MissionManagement TeamScientific Advisory BoardBoard of Directors Directors Nobuyuki Ota PhD Nigel Ten Fleming PhD Shirley Lui Clayton MBA Menghis Bairu MD Stefan Ryser PhD Ben duPont Umeda Kazuhiro 2010 A-CUBE, Inc. All Rights Reserved | Terms & Conditions | Privacy Policy ...

MissionManagement TeamScientific Advisory BoardBoard of Directors Mission A-CUBE utilizes in silico algorithms and bioinformatics (genomics and proteomics) to discover novel druggable targets suitable for developing human therapeutic interventions, including next generation drugs for commercially pr...

Technology SummaryProof of Concept Technology Summary A-Cube is the technology leader in identifying B-cell epitopes, the binding sites for antibodies, e.g., monoclonal antibodies and neutralizing antibodies. A-Cube's proprietary algorithms RAD (Rational Antigen Design) and R-RAD (Reverse RAD) were ...

Investor Relations Investor Relations To date A-CUBE investors include the Japanese venture capital firms Japan Asia Investment Co Ltd (JAIC, Tokyo), Tissue Engineering Initiative (TEI, Tokyo), Bio-Sight Capital (Tokyo), and most recently JAIC-USSII (Delaware). Please contact us to inquire about inv...

MissionManagement TeamScientific Advisory BoardBoard of Directors Management Team Nobuyuki Ota PhD Co-Founder, President & Chief Scientific Officer Dr. Ota is Co-Founder, President and Chief Scientific Officer of A-CUBE, INC. He also holds the post of Adjunct Professor at Tokyo University of Sci...